Ads for OTC Meds Downplay Risks

 

Those direct-to-consumer ads for prescription drugs that include a long list of potentially harmful side effects give way to less scary commercials when the same meds become available over-the-counter. In other words, you may be led to believe that a medication is safer than it really is. That is the finding of a study by Jeremy A. Greene, MD, PhD of Brigham and Women's Hospital in Boston and colleagues that was published in the Journal of the American Medical Society.

 

"The US Food and Drug Administration (FDA) regulates prescription drug advertising, including requirements to provide consumers with a 'fair balance' of risks and benefits," the authors wrote. "When prescription drugs switch to over-the-counter (OTC) status, regulatory oversight of their advertising shifts to the Federal Trade Commission (FTC). Unlike the FDA, the FTC holds drug advertisements to the same standards as any consumer product: it applies a 'reasonable consumer' standard of truthfulness and nondeception that does not require any balancing of potential benefits and harms. Such a shift may be associated with changes in content."

The investigators analyzed all print and broadcast advertisements for four commonly used prescription drugs that were the subject of extensive direct-to-consumer promotion before and after OTC shift: loratidine (Claritin and others for allergies), omeprazole (Prilosec and others for acid reflux), orlistat (Alli and others for weight loss), and cetirizine (Aller-Tec and others for allergies). Television and print materials spanning 24 months before and six months following the OTC shift for each drug were obtained from an advertising database.

After the OTC switch, with the exception of print advertisements for orlistat, no postswitch advertisements mentioned contraindications or adverse effects. Also, 97% of the advertisements described benefits of medications compared with 83% during the prescription only period. In a comment on their study, the authors wrote: "Our results support and extend initial reports on the practical outcomes of the shift in regulatory oversight in drug promotion from the FDA to the FTC that accompany OTC shift. In addition to less presentation of potential harms, DTCA for OTC medications frequently omitted identification of drugs by their generic names, both of which are key tools for consumers seeking independent information on risks, benefits, and costs . . . Pharmaceuticals do not lose their capacity for harm after moving from behind the pharmacist's counter to in front of it; misuse of OTC drugs remains a major cause of emergency department visits, hospitalization, and death. Closer attention should be paid to how such drugs are promoted to consumers." Until that happens, the lesson here is to read the labels and warnings on any OTC drug you are considering purchasing. Don't be lulled by advertisements into thinking the meds being purveyed are safe!
1 2 Next
Print Article